Employees are asked to donate blood for experiments in exchange for $75 gift cards.

According to Endpoints News, covid vax business is in trouble – both Pfizer and Moderna are tanking, and heads of sales have departed:

[Moderna] reaffirmed its focus on driving Covid-19 and soon RSV vaccine sales, though the former’s sales have been challenged by waning demand. Moderna said last month that it expects Covid sales to “hit a low point” in 2024, while Pfizer recently slashed expectations for its Comirnaty shot by $2 billion.

Pfizer also announced an executive shake-up on Tuesday. Chief commercial officer and global biopharma president Angela Hwang will depart after 27 years at the pharma giant as the company creates two non-oncology commercial units.

…the company prepares to launch its RSV vaccine in 2024 and promises to deliver “multiple products per year from 2025 forward.” The company stuck to its full-year 2023 sales guidance of $6 billion to $8 billion on its latest quarterly call, but said the low end is more realistic, also noting a $1.3 billion write-down for “excess and obsolete” Covid product. Executives expect 2024 revenue to be around $4 billion.